BiotechTube

ABBV-383 (Etentamig)

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin Light Chain (AL) Amyloidosis

Conditions

Immunoglobulin Light Chain (AL) Amyloidosis

Trial Timeline

Apr 1, 2024 → Sep 1, 2031

NCT ID
NCT06158854

About ABBV-383 (Etentamig)

ABBV-383 (Etentamig) is a phase 1/2 stage product being developed by AbbVie for Immunoglobulin Light Chain (AL) Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06158854. Target conditions include Immunoglobulin Light Chain (AL) Amyloidosis.

What happened to similar drugs?

0 of 4 similar drugs in Immunoglobulin Light Chain (AL) Amyloidosis were approved

Approved (0) Terminated (0) Active (4)
🔄iptacopanNovartisPhase 3
🔄Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
🔄Felzartamab + PlaceboBiogenPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06158854Phase 1/2Recruiting

Competing Products

11 competing products in Immunoglobulin Light Chain (AL) Amyloidosis

See all competitors
ProductCompanyStageHype Score
zigakibartNovartisPhase 2
42
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
InebilizumabAmgenPhase 2
42
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
47
rilzabrutinib + GlucocorticoidsSanofiPhase 2
35
FelzartamabBiogenPhase 2
32
Felzartamab + PlaceboBiogenPhase 3
44
SparsentanTravere TherapeuticsPhase 2
29
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38